8-KMaterial AgreementsRegulation FDExhibits & Filings

ELI LILLY & Co 8-K Report, Material Agreement (Jan 7, 2019)

Filed January 7, 2019For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on January 7, 2019, to disclose information related to a significant event, as detailed in Item 1.01 of the report. This 8-K primarily serves to attach and incorporate by reference a joint press release issued by Eli Lilly and Loxo Oncology, Inc. on January 7, 2019, and an investor presentation dated January 2019. These documents are expected to provide crucial details regarding the matters discussed, likely pertaining to a corporate development or strategic announcement between the two companies. Investors should review these attached exhibits for a comprehensive understanding of the business implications. The attached press release and investor presentation are key resources for understanding the nature of the announcement. While the 8-K itself is procedural, the appended materials are where the substantive investor information resides. Investors are advised to focus on Exhibits 99.1 and 99.2 to gain insights into potential partnerships, acquisitions, or other material business developments that could impact Eli Lilly's future performance and strategic direction.

Key Highlights

  • 1Eli Lilly (LLY) filed an 8-K on January 7, 2019, indicating a material event.
  • 2The filing incorporates by reference a joint press release from Eli Lilly and Loxo Oncology, Inc. dated January 7, 2019.
  • 3An investor presentation from Eli Lilly, dated January 2019, is also attached and incorporated.
  • 4These exhibits (99.1 and 99.2) are the primary source of information regarding the disclosed event.
  • 5The 8-K itself is largely procedural, directing investors to the attached press release and presentation for details.
  • 6The information is furnished under Regulation FD and not deemed 'filed' for certain legal purposes.

Frequently Asked Questions

The primary purpose of this 8-K filing is to formally disclose and incorporate by reference a joint press release and an investor presentation concerning a significant event involving Eli Lilly and Loxo Oncology, Inc. These attached documents contain the substantive details of the announcement.

The key information is primarily contained within Exhibit 99.1 (the Joint Press Release issued by Eli Lilly and Loxo Oncology, Inc.) and Exhibit 99.2 (the Investor Presentation of Eli Lilly and Company), both dated January 2019, which are attached to this 8-K filing.

No, the information furnished under Item 7.01, including the attached exhibits, is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 or subject to its liabilities. It is furnished information, not formally filed.

The filing indicates a joint press release and a shared investor presentation, suggesting a significant business interaction or development between Eli Lilly and Loxo Oncology, Inc. Investors would need to consult the exhibits to understand the specific nature of this relationship (e.g., acquisition, partnership, licensing deal).